TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers at Chalmers University of Technology report that blood-protein patterns associated with triglyceride-rich lipoproteins (TRL) and lipoprotein(a) (Lp(a)) were linked to later heart disease. The findings offer clues about why risk can persist after LDL cholesterol falls, but do not show that the particles caused disease or establish a new treatment.
Researchers at Chalmers University of Technology in Sweden say protein patterns associated with two blood fat-carrying particles, TRL and Lp(a), were linked to the later development of heart disease. The findings offer possible biological clues to why some people remain at risk even after lowering LDL cholesterol, but they do not establish that these particles caused heart disease or that changing their levels would prevent heart attacks.
The team examined blood measurements of nearly 3,000 proteins and compared them with genetic information and long-term health records. The researchers studied proteins associated with three lipoprotein types: LDL, triglyceride-rich lipoproteins (TRL), and lipoprotein(a) (Lp(a)). Lipoproteins carry fats through the bloodstream; LDL is the best-known carrier associated with cholesterol buildup in artery walls.
The report says protein patterns linked to TRL and Lp(a) had substantial similarities, despite the particles being distinct. Those overlapping patterns were also associated with later heart disease. This points to biological activity that may matter beyond the amount of cholesterol measured in an LDL test. The source material does not provide the study’s sample size, effect estimates, or detailed methods, so the strength and scope of the association cannot be judged from the report alone.
Lead author Jakub Morze, a postdoctoral fellow at Chalmers, said the researchers wanted to investigate what happens beyond cholesterol accumulation and whether different fat-carrying particles affect blood vessels differently. The study’s approach was proteomics: measuring proteins in blood to identify patterns related to biological processes. The findings are research clues, not a clinical test or a treatment recommendation.
Risk Beyond LDL Cholesterol
LDL-lowering treatment is a proven way to reduce the likelihood of heart attack, but lowering LDL does not remove every source of cardiovascular risk. The study adds to research into why some patients still develop coronary heart disease after LDL reaches recommended levels. Its focus on TRL and Lp(a) may help researchers identify additional pathways involved in that remaining risk.
For readers, the practical message is not to stop or change cholesterol treatment based on these findings. The report does not show that measuring the identified protein patterns can predict an individual’s outcome, nor that treating TRL or Lp(a) according to this study prevents events. Decisions about personal risk and medication should be made with a qualified health professional, using the full clinical picture rather than a single research finding.
Products Worth Considering
Oura Ring 5 Smart Ring, Gold, Size 10
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Levoit Core 400S-P Smart Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
How Blood-Fat Particles Relate
Cholesterol and other fats travel through blood inside lipoproteins. When cholesterol-carrying particles contribute to deposits in artery walls, plaques can narrow the vessels. If a plaque ruptures, a clot may block blood flow and cause a heart attack or stroke. LDL is a major focus of prevention because lowering it reduces risk, but it is not the only particle that carries fats.
The researchers’ earlier work, as described in the report, found that counting harmful lipoprotein particles was a strong way to predict future heart disease risk. That work also identified TRL and Lp(a) as contributors that may matter alongside LDL. The new investigation shifts attention from particle counts and cholesterol alone toward proteins associated with the particles, seeking clues about possible differences in how they relate to blood-vessel damage.
Cardiovascular disease remains a major global health burden. The source report cites the World Health Organization’s estimate that these diseases cause nearly 17.9 million deaths worldwide each year, with heart attacks and strokes accounting for more than 80% of those deaths. Those figures describe the broader disease burden, not outcomes measured in this study.
“For this study, we wanted to understand what happens beyond the accumulation of cholesterol in artery walls, whether different fat-carrying particles can damage the blood vessels differently and why the remaining risk of heart disease still occurs.”
— Jakub Morze, lead author and postdoctoral fellow at Chalmers University of Technology
What the Findings Do Not Establish
The report describes associations between protein patterns and later heart disease; it does not establish that the patterns or the associated particles caused the disease. The supplied material does not identify the number or characteristics of participants, the length of follow-up, the size of the observed risks, or whether researchers accounted for relevant potential confounders. It also does not specify how the protein findings compared across participant groups.
It remains unclear whether these patterns can improve risk prediction beyond established clinical measures, which particular proteins matter most, or whether acting on them would change outcomes. The report provides no evidence that a new screening test or treatment is ready for clinical use. Further research would be needed before the findings could guide routine care.
From Protein Patterns to Patient Care
The next step is to determine whether the protein patterns hold up in additional populations and whether they add useful information to existing cardiovascular risk assessments. Researchers would also need to test whether the suspected biological pathways contribute directly to artery damage, rather than simply appearing alongside other risk factors.
Any move toward patient care would require evidence that a test reliably identifies risk and that an intervention based on the result improves health outcomes. Until such evidence is available, LDL-lowering care remains important, and patients should discuss their cholesterol results and overall heart risk with their clinicians rather than interpreting this study as a reason to change treatment.
Key Questions
How can heart disease develop when LDL cholesterol is low?
Lower LDL reduces heart attack risk, but it does not eliminate all risk. Other factors, including particles such as TRL and Lp(a), may contribute to cardiovascular disease. The study offers biological clues but does not determine an individual’s cause of risk.
What did the Chalmers researchers examine?
They analyzed measurements of nearly 3,000 blood proteins alongside genetic information and long-term health records, looking for protein patterns associated with LDL, TRL, and Lp(a).
Does the study prove TRL or Lp(a) causes heart attacks?
No. The reported findings are associations between particle-related protein patterns and later heart disease. They do not prove causation or show that treating either particle would prevent heart attacks.
Should someone change cholesterol medication because of this report?
No treatment change follows from the findings described. LDL-lowering treatment is an established way to reduce heart attack likelihood. Discuss personal results, medication, and overall risk with a qualified health professional.
Source: sciencedaily.com
